Welcome to our dedicated page for GSK PLC news (Ticker: GSK), a resource for investors and traders seeking the latest updates and insights on GSK PLC stock.
News and regulatory disclosures for GSK plc (GSK) highlight the company’s ongoing activity across medicines, vaccines and strategic collaborations. As a global biopharma company, GSK regularly reports clinical trial milestones, product approvals, public health initiatives and agreements with partners and governments.
Recent news includes multiple regulatory approvals and data readouts in respiratory medicine. GSK has announced approvals for Exdensur (depemokimab) in markets such as Japan for severe asthma and chronic rhinosinusitis with nasal polyps, based on the SWIFT and ANCHOR phase III trials. The company has also reported that Nucala (mepolizumab) was approved in China as an add-on maintenance treatment for adults with COPD characterized by raised blood eosinophils, supported by the MATINEE and METREX studies.
In vaccines, GSK issues updates on Shingrix, including US FDA and European Commission approvals of a prefilled syringe presentation designed to simplify administration, and on its seasonal influenza vaccines FLULAVAL and FLUARIX, which are shipped ahead of each US flu season following FDA lot-release. News about Vaccine Track, GSK’s public data tool for US adult immunization trends, provides additional context on the company’s role in vaccination and public health analytics.
Oncology and specialty medicine updates feature prominently in GSK news. The company has reported US FDA approval of Blenrep in combination regimens for relapsed or refractory multiple myeloma, as well as positive phase III results for bepirovirsen in chronic hepatitis B with plans for global regulatory submissions. Additional releases describe collaborations with partners such as Hengrui Pharma and Summit Therapeutics to develop new respiratory, immunology & inflammation and oncology programs.
Investors and observers following GSK news can expect coverage of clinical trial outcomes, regulatory decisions, pricing and access agreements, and community initiatives such as the Linked by Lupus: Optimal Care Initiative. Bookmarking this page provides a centralized view of GSK’s latest announcements and SEC-reported developments.
GSK and IQVIA have launched Vaccine Track, a new platform to enhance data transparency regarding adult vaccinations in the US. This resource aims to address the decline in adult immunization rates, particularly among minority populations, which saw an 18% drop in overall claims for recommended vaccinations from 2019 to 2021. The platform provides quarterly updates and diverse trend analyses, supporting public health efforts to improve vaccination rates post-pandemic. The initiative emphasizes the importance of vaccination data and could significantly impact public health policy.
GSK has received FDA approval for Benlysta (belimumab), making it the first biologic treatment for children aged 5 to 17 with active lupus nephritis (LN). This approval expands Benlysta's indications in the U.S. to include both lupus and active LN in pediatric patients. Lupus nephritis can lead to severe kidney complications. The treatment focuses on preserving renal function while reducing toxicities associated with traditional therapies. GSK aims to enhance treatment options and outcomes for children facing this serious condition.
GSK has initiated shipping of its FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT influenza vaccines to US healthcare providers for the 2022-23 season, following FDA approval. The company aims to distribute over 50 million doses to support annual immunization efforts. Despite extensive public health campaigns, vaccination rates in the US remain consistent with previous seasons. GSK emphasizes the need for increased awareness, particularly in underserved communities. Both vaccines are approved for patients aged six months and older, aligning with CDC recommendations.
GSK has awarded the inaugural £70,000 grant (about $100,000) to the
GSK has received FDA approval for PRIORIX, a measles, mumps, and rubella (MMR) vaccine, aimed at individuals aged 12 months and older. This marks the vaccine's debut in the US market, where it adds to GSK's pediatric vaccine offerings, currently distributed in over 100 countries with more than 800 million doses. The FDA's approval comes in response to recent measles outbreaks and declining vaccination rates in children, emphasizing the need for additional vaccine options to protect against these highly-contagious diseases.
Summary not available.
GlaxoSmithKline's TUMS®, America’s leading heartburn brand, has launched a new campaign titled 'Love Food Back', aimed at encouraging consumers to embrace their favorite foods without fear of heartburn. This campaign pivots from a decade-long focus on combating heartburn to celebrating food enjoyment. The strategy includes interactive elements, such as the TUMS® Cam Sweepstakes, and features engaging advertisements showcasing humorous relationships between consumers and food. The campaign aims to redefine the emotional association with food and heartburn relief.
Pfizer announced plans to exit its 32% ownership interest in Haleon, the new standalone company formed post-GSK demerger. This move aims to maximize shareholder value. The demerger, involving GSK transferring approximately 80% of its consumer healthcare business to GSK shareholders, will be completed by July 2022. Haleon will also pursue a listing on the New York Stock Exchange. Key legal and financial advisors, including Morgan Stanley and Guggenheim Securities, are engaged in the process. This strategic decision aligns with Pfizer's focus on innovative medicines and vaccines.
GSK Consumer Healthcare has launched CareWalks, an initiative to support caregivers, in partnership with actress Jennie Garth. This program provides resources and encourages movement to alleviate pain associated with caregiving duties. Data reveals that 94% of caregivers report musculoskeletal pain, with many struggling to provide care due to this discomfort. The initiative includes a video series featuring caregivers' stories, email resources, and a charitable donation to Volunteers of America. Voltaren Arthritis Pain Gel is highlighted as a key product for managing osteoarthritis pain.
MOBItalks returns to New York on May 14, 2022, focusing on alternative wellness and community empowerment for Black gay men. Presented by ViiV Healthcare and the Mobilizing Our Brothers Initiative (MOBI), the event features speakers and provides networking opportunities. Attendees can enjoy free professional headshots and brunch by Cornbread26 Food Co. MOBI, active since 2017, aims to enhance personal development and community wellness, having contributed over $1 million to the Black queer community. For registration, visit mobi-nyc.com/nyctalks.